BioSpace News Archive

Global prevalence of systemic and localized autoimmune disorders, emergence of various government initiatives and enhanced ability to spend on the treatment of these ailments will stimulate autoimmune disease diagnostics market trends.

Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company has received the CE-IVD mark for its Advanta™ Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus. The CE-IVD mark is in conformance with the European Union In Vitro Diagnostic Directive. T

Adamis Pharmaceuticals Corporation announced that its SYMJEPI® Injection products are now available to members of the Walgreens Prescription Savings Club program, for a discounted price of $99.99 for a two-pack, the lowest price offered for epinephrine products through the Walgreens Prescriptions Savings Club, and the lowest price for epinephrine devices on the market1.

Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced financial results for the quarter ended December 31, 2020.

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX, and HCQ) are now a contracted in-network service with Tufts Medical Center, an internationally-respected academic medical center. “Autoimmune diseases are challenging for healthcare providers to diagn

Nascent Biotech, Inc. Nascent Biotech Research Partner, Manhattan BioSolutions (MABS), Inc. announced that it will be presenting at the ACCESS CHINA Forum at JP Morgan Week 2021; which is being held online on January 4 th to 30 th , 2021.

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. Th

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (“efti” or “IMP321”) and IMP761, and the activities of its partners.

CABENUVA offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression

DW Healthcare Partners V, L.P., announced that it is extending the expiration time of its previously announced cash tender offer in the Offer to Purchase dated December 21, 2020 for all of the outstanding ordinary shares of Parnell Pharmaceuticals Holdings Ltd at a price of U.S.$0.40 per share, net to the seller in cash without interest and less applicable withholding taxes to 11:59 p.m., New York City time, on January 28, 2021.